Keywords: Eisai, Morphotek, Farletuzumab, Ovarian cancer, Ph III, Missed endpoint
Eisai/Morphotek's farletuzumab fails on ovarian cancer Ph III trial
Article | 14 January 2013
USA-based Morphotek, a wholly-owned subsidiary of Japanese drug major Eisai (TYO: 4523) which acquired the firm for $325 million in 2007, presented disappointing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
